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S u m m a r y
Hypertension is one of the most common diseases worldwide and still leading risk factor 
for cardiovascular mortality and disability. In Poland it affects about 32% of adult population, 
but blood pressure (BP) control is achieved only in every fourth patient. The review focus-
es on contemporary management of high blood pressure (BP) and underlines benefits of 
therapy for life expectancy in EU countries and in Poland. On the other hand we discuss the 
impact of high BP and its treatment on health-related quality of life (HRQoL). Recently per-
formed studies showed a lower HRQoL in patients on antihypertensive treatment both with 
and without BP control, in comparison with hypertensives who did not receive treatment. 
Moreover, improvement of the HRQoL in patients with hypertension depends on numerous 
factors, not only BP control during antihypertensive therapy. Thus, the knowledge of the 
patient’s well-being has considerable practical implications, especially in chronic diseases 
like arterial hypertension, which are associated with long-term or even lifelong treatment.
S t r e s z c z e n i e
Nadciśnienie tętnicze jest jednym z najbardziej rozpowszechnionych schorzeń na 
świecie, wiodącym czynnikiem ryzyka umieralności z powodów sercowo-naczyniowych 
oraz powodem niesprawności. W Polsce nadciśnienie dotyczy około 32% dorosłej popu-
lacji, a kontrolę ciśnienia tętniczego uzyskuje się tylko u 1/4 leczonych. Prezentowana pra-
ca dotyczy nowoczesnego leczenia nadciśnienia tętniczego, podkreślając jego korzystny 
wpływ na przedłużanie życia chorych w krajach Unii Europejskiej i w Polsce. Dyskutowany 
jest również wpływ wysokich wartości ciśnienia i farmakoterapii na jakość życia uwarunko-
waną stanem zdrowia (HRQoL). Ostatnio prowadzone badania wskazują na niższą jakość 
życia chorych na nadciśnienie leczonych farmakologicznie, niezależnie od skuteczności 
leczenia, w porównaniu z chorymi, u których nie wdrożono leczenia. Ponadto wiadomo, że 
poprawa HRQoL u chorych na nadciśnienie jest uwarunkowana wieloma czynnikami, nie 
tylko kontrolą ciśnienia. Wiedza na temat samopoczucia pacjenta jest szczególnie istotna 
w chorobach przewlekłych, takich jak nadciśnienie tętnicze, w których leczenie trwa wiele 
lat, a często całe życie.
Hypertension is one of the most common diseases 
and its prevalence in adult population worldwide was 
26% in the year 2000 and is estimated to reach 29.2% 
in the year 2025.
In Poland, according to the NATPOL epidemiolog-
ical studies it occurs in 32% (35% males and 29% fe-
males) of population aged 18-79 years (1).
According to the CSO data (Health Status of the 
Polish Population in 2004), high blood pressure (BP) 
is reported by 20.7% men and 25.2% women as the 
second most common disease/chronic illness report-
ed (CSO 2016).
According to WHO, high blood pressure is the most 
common risk factor of death in the world (fig. 1).
Currently, as in previous years, cardiovascular dis-
eases, including hypertension and its complications 
such as stroke and myocardial infarction are the cause 
of more than 45% of all deaths in Poland (tab. 1).
Cardiovascular deaths in Poland increased steadily 
through the 1970s and 1980s, but from 1991 to 2005 
the death rate decreased (2).
About 54% of the fall of mortality due to coronary 
heart disease (the most common cause of deaths 
among the diseases of circulatory system) was attrib-
uted to changes in risk factors but not BP (fig. 2). Blood 
pressure fall in women explaining about 29% of their 
decrease in mortality, but in men generating a negative 
influence – 8% increase in mortality (3).
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In recent years, trends in hypertensive disease mor-
tality rates are favorable (tab. 2).
Trends in hypertensive disease mortality rates in Po-
land in the years 2008-2014 are presented in table 2.
Despite the continuous decrease, in Poland cardio-
vascular mortality is still higher than in 15 EU coun-
tries (fig. 3).
Data from Eurostat covering the period 2005-2014 
prove that life expectancy for both men (tab. 3) and 
women (tab. 4) has increased.
However, similar to the most Central and East Eu-
ropean countries, life expectancy at age of 45 years is 
still shorter in Poland in comparison with EU 15 coun-
tries from before 2004 (fig. 4).
Complications of hypertension, such as stroke, cor-
onary heart disease, heart and renal failure influence 
the longevity of life in health.
In the years 2005-2014, the expectancy of life in good 
health in Poland has reduced (tab. 5).
Hypertension according to the 2012 World Health 
Statistic for middle-income countries in 2004 was the 
Fig. 1. Mortality risk factor in middle-income countries in 2004 (World 
Health Statistics 2012, WHO 2012)
Tab. 1. Major death causes in Poland
Death  causes (over 100 
thousand inhabitants)
Year 2014
Total Males Females
Cardiovascular diseases 
including:
 coronary artery disease
 cerebrovascular disease
441.1
100.1
80.6
423.2
19113.0
71.8
457.8
88.1
88.8
Diseases of arteries, arterioles 
and capillaries, including: 
 atherosclerosis
 hypertensive disease
98.6
92.4
10.2
75.4
67.3
9.0
120.2
115.9
11.4
Total 978.2 1051.3 909.7
Small Statistical Yearbook of Poland, CSO, 2016 (4)
Fig. 2. Explaining the fall in coronary artery disease mortality in Po-
land between 1991 and 2005 (3)
Tab. 2. Trends in hypertensive disease mortality rate
Hypertensive disease as death cause 
(over 100 thousand inhabitants/year) 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Males 12.5 13.8 14.0 13.0 14.2 14.2 12.4 10.7 9.9 9.0
Females 16.6 17.4 17.0 16.4 18.1 18.4 15.9 13.0 12.3 11.4
Based on consecutive editions of the Small Statistical Yearbook of Poland, CSO 2007-2016 (4)
Tab. 3. Life expectancy for men at birth
Area/year 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
EU (28 countries) 75.4 75.8 76.0 76.3 76.6 76.9 77.3 77.4 77.8 78.1
Poland 70.8 70.9 71.0 71.3 71.6 72.2 72.5 72.6 73.0 73.7
Tab. 4. Life expectancy for women at birth
Area/year 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
EU (28 countries) 81.5 82.0 82.2 82.3 82.6 82.8 83.1 83.1 83.3 83.6
Poland 79.3 79.7 79.8 80.0 80.1 80.7 81.1 81.1 81.2 81.7
Fig. 3. Age-standardized cardiovascular disease mortality rates in 6 Cen-
tral & Eastern European Countries and European Union (15 countries be-
fore May 2004). Source: Health for All Database, WHO Europe, 2015 (5)
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second risk factor of DALY (disability-adjusted life 
years) (fig. 5). By contrast, in Poland at that time smok-
ing was the first risk factor. Elevated blood pressure 
was responsible for 10.4% of all lost life years.
According to Rahim et al. (6) elevated BP is the 
leading risk factor for mortality and morbidity account-
ing for 7% of global disability adjusted life years and 
9.4 million deaths in 2010. Global age-standardised BP 
has decreased during the past 30 years, however the 
number of individuals with uncontrolled hypertension 
increased from 605 to 978 million because of popula-
tion growth and ageing. As a result, high BP increased 
from the fourth ranked risk factor for burden of disease 
in 1990 to the leading risk factor in 2010.
In Poland, the control of blood pressure in the last 
decade (in the years 2004/2005-2014/2015) has largely 
improved; from 10 to 23% in men and from 16 to 35.3% 
in women (unpublished data from WOBASZ I and II 
studies). Still, compared to the US, Canada and West-
ern European countries, it is lower. Hypertension is in 
Poland and in the world the major cause of DALY loss.
The benefits of BP lowering treatment for prevention 
of cardiovascular disease are well established. In late 
1960’s the Veteran Affairs Cooperative Study based on 
pharmacological treatment provided the first strong cas-
ual evidence the BP lowering reduces the risk of death.
Over the next decades clinical studies on the treat-
ment of hypertension and other cardiovascular risk fac-
tors were conducted and target blood pressure values 
for the population of patients were determined.
Recently several randomised trials compared the ef-
fect of a more versus less intensive BP lowering strat-
egy on the risk of major cardiovascular events and 
death, including the SPRINT Trial initiated by National 
Health Institutes of USA (7, 8). The results of the meta-
analyses published by Xie et al. (9), Ettehad et al. (10), 
Verdecchia et al. (11) (the latter included the results 
of SPRINT trial) confirmed the evidence supporting the 
benefits from more intensive BP lowering strategies.
HEALTH-RELATED QUALITY OF LIFE
The effectiveness of antihypertensive therapy in dai-
ly clinical practice in Poland is not satisfactory. Blood 
pressure (BP) control is achieved only in every fourth 
patient, and there is still a discrepancy between a wide 
selection of modern antihypertensive drugs and a low 
percentage of patients achieving target BP values. One 
of the major reasons behind the low effectiveness of 
antihypertensive therapy is noncompliance with treat-
ment recommendations, which may be associated, 
among others, with multiple adverse effects of drugs 
affecting the patient’s well-being.
The assessment of so called health-related quality 
of life (HRQoL) allows patient-oriented monitoring of 
treatment outcomes, namely, a monitoring that involves 
the individual experience and expectations of a patient. 
Modern therapy of chronic diseases focuses on max-
imizing the efforts to prolong life expectancy, and sig-
nificant achievements have been observed in this field. 
However, it is important not only to know whether a drug 
prolongs the life of patients, but also how it affects their 
well-being, their ability to perform daily activities and 
social roles, their satisfaction with their current health 
status, their physical and mental condition, as well as 
other areas of life (12). From the patient’s perspective, 
whether and how the patient will comply with treatment 
recommendations depends on the above aspects of 
health, which today can be carefully measured (13).
The knowledge of the patient’s HRQoL has con-
siderable practical implications, especially in chronic 
diseases, which are associated with long-term or even 
lifelong treatment (14). In clinical practice, we often en-
counter patients who display symptoms of low inten-
sity, or even no symptoms, at early stages of their dis-
Fig. 4. Life expectancy at age 45 in 6 Central & Eastern European 
Countries and European Union (15 countries before May 2004) (5)
Tab. 5. Life expectancy in good health in Poland
Poland/year 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Males 61.2 58.4 57.6 58.6 58.3 58.5 59.1 59.1 59.2 59.8
Females 66.9 62.9 61.5 63.0 62.5 62.3 63.3 62.8 62.7 62.7
Fig. 5. Risk factors of disability adjusted life-years (DALY) in middle-
income countries in 2004 (World Health Statistics 2012, WHO 2012)
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eases (e.g., mild or moderate hypertension). In these 
patients, lifestyle modification is usually recommended 
at the initial stage, with a number of patients requiring 
long-term pharmacological treatment. This treatment 
usually does not bring an immediate, direct effect felt 
by a patient; nevertheless, it should be instituted and 
continued to prevent complications that reduce life ex-
pectancy (15).
FACTORS MODIFYING THE QUALITY OF LIFE 
IN PATIENTS WITH HYPERTENSION
In studies on HRQoL, mild or moderate hypertension 
is used as a model for all asymptomatic cardiovascular 
diseases that require chronic treatment. Most patients 
with hypertension do not experience symptoms, espe-
cially at early stages of the disease, and yet, their qual-
ity of life (QoL) is lower than that of healthy individuals 
matched for age. The difference ranges from 5 to 15%, 
depending on assessment methods and age of study 
participants (16). Some researchers claim that the low-
er QoL results from the specific effect of hypertension 
itself, while others attribute it to the effect of diagnostic 
labeling (i.e., after diagnosis patients experience anx-
iety, stress, and symptoms not experienced before). 
Even lower QoL is observed in hypertensive patients 
with concomitant coronary artery disease, arrhyth-
mias, and, particularly, with heart failure. The presence 
of cardiovascular risk factors, such as lipid disorders, 
obesity, and low physical activity, is also associated 
with a reduced QoL. The higher the number of risk fac-
tors in a patient, the lower his or her HRQoL. It is esti-
mated that the quality-adjusted life expectancy (QALE) 
in middle-aged and elderly patients with hypertension 
is approximately 6 years shorter than that in individuals 
without hypertension, and this is specifically attribut-
ed to a reduced QoL (17). The effect of hypertension 
on the reduction in QALE can be observed already in 
younger adults. Long-term population-based studies 
cited earlier showed that QALE is shorter by 2.2 years 
in 18-year-old patients with hypertension, as compared 
with age-matched healthy controls. It is also known 
that in patients older than 50 years of age increased 
BP values account for 15% of disability measured by 
disability-adjusted life years (DALYs), and in those old-
er than 70 years of age – for 20%. Of note, the defi-
nition of DALY also includes QoL (18). A recent large 
prospective trial showed that low QoL in normotensive 
individuals is associated with the development of hy-
pertension, independently of the presence of tradition-
al risk factors, at least in women (19).
It is known that a reduced HRQoL in middle-aged 
hypertensive patients (by 10 to 20% in comparison 
with normotensive individuals) is associated with high-
er mortality from cardiovascular causes, independent-
ly of the presence of traditional risk factors. According 
to population-based studies, HRQoL in hypertensive 
women is lower than that in age-matched hypertensive 
men (20). A similar difference in QoL between men and 
women can be observed in the general population, 
and the reasons for this phenomenon are complex. 
Nevertheless, in hypertensive women, the QoL starts to 
deteriorate earlier (often already after 35 years of age) 
and more rapidly than in healthy women. The above 
factors affecting HRQoL indirectly contribute to a wide 
prevalence of resistant hypertension by hindering its 
treatment and worsening prognosis (21).
Apart from sex-related differences, one of the most 
important factors affecting the QoL is age. Elderly peo-
ple have a significantly lower HRQoL than young indi-
viduals. In our study including 1000 outpatients with 
hypertension, reduced QoL was observed in a 6-year 
follow-up in both sexes (fig. 6). At the same time, an 
improvement in BP control was observed, from 31% of 
patients at baseline to 51% at 6 years. However, even 
in patients with good BP control, the QoL at 6 years 
was reduced. This observation suggests that achieving 
BP control is not equivalent to improved QoL and that 
other conditions have to be met for the QoL to improve 
during treatment.
Other factors that lead to a considerably reduced 
QoL in patients with hypertension include low educa-
tional and socio-economic status, disability, social iso-
lation, and low level of social support. These factors 
directly affect the effectiveness of treatment because 
such patients are characterized by poor compliance 
with treatment, lower awareness of the importance of 
self-care, and, as shown by epidemiological studies, 
by increased cardiovascular risk. The presence of co-
morbidities, which are a source of negative physical 
and emotional symptoms, is another reason for an 
age-related reduction in QoL.
An important problem associated with pharma-
cological treatment of hypertension is the presence 
of adverse effects, which contribute to the low effec-
tiveness of therapy. Some of the symptoms are non-
specific (e.g., headache), others are clearly related to 
a drug class (e.g., cough during treatment with angio-
tensin-converting enzyme inhibitors), or, for example, 
bradycardia occurring during treatment with β-adre-
nolytics. It is commonly believed that antihypertensive 
drugs produce only few or nonserious adverse effects. 
Fig. 6. Changes in the quality of life in men (age, 46.0 ± 14.6 years) 
and women (49.6 ± 12.4 years) treated for hypertension on an out-
patient basis for 6 years
***p < 0.001 males vs females
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There are several reasons for this. First, in the method-
ology of clinical trials, it is the researcher and not the 
patient that assesses so called drug tolerance. Second, 
the subjective opinion of a patient on the effectiveness 
of treatment is not treated as valuable information and 
is usually neglected. Third, researchers focus more on 
so called hard endpoints (e.g., mortality) rather than 
on patients themselves and their problems (such as 
well-being, physical and mental condition, ability to 
perform social roles). Finally, clinicians lack experience 
in the measurement and interpretation of data on QoL 
and self-reported health status.
Studies, including those conducted in Poland, have 
long shown that only from 20 to 25% of patients on an-
tihypertensive treatment spontaneously report adverse 
effects to their physicians, while more than 70% of pa-
tients actually experience them (22). Trevisol et al. (23) 
showed a lower QoL in patients on antihypertensive 
treatment both with and without BP control, in com-
parison with hypertensive patients who did not receive 
treatment. The number of drugs used is a clinically 
useful marker of the QoL. In outpatients with hyperten-
sion, an inverse correlation was observed between the 
number of antihypertensive drugs used and HRQoL.
IMPROVEMENT OF THE QUALITY OF LIFE 
IN PATIENTS WITH HYPERTENSION
Improvement of the HRQoL in patients with hyper-
tension depends on numerous factors, one of which 
is BP. Prospective studies have shown that BP reduc-
tion slightly slows down the process of lowering of the 
QoL, as it exerts a positive effect on cognitive function, 
well-being, physical condition, and vitality of patients. 
Studies on the treatment of isolated hypertension in 
elderly patients have also revealed that antihyperten-
sive therapy may reduce the incidence of dementia. 
However, it is unknown whether these beneficial ef-
fects are permanent, because most data come from 
studies lasting from 12 weeks to 4 years. In addition, 
some of the more important studies, especially those 
in elderly people (Syst-Eur, HYVET), did not show an 
improvement in QoL during antihypertensive treatment 
despite improving BP control and prolonging the life of 
patients (24, 25).
According to numerous studies on large popula-
tions, modern antihypertensive drugs, irrespective of 
a drug class, significantly prolong life expectancy (26). 
However, from the perspective of the patient’s HRQoL, 
the choice of a particular treatment is of key impor-
tance. Recently, Thomopoulos et al. have reported 
that in every 1000 patients, a reduction of 33 major 
cardiovascular events is related to as many as 89 pa-
tients discontinuing treatment due to these adverse 
effects (27).
The analysis of individual drug classes revealed that 
angiotensin-converting enzyme inhibitors, angioten-
sin II receptor blockers (sartans), newer β-blockers, 
and long-acting calcium channel blockers are associ-
ated with a minor improvement in the QoL, while cen-
trally acting antihypertensive drugs and direct-acting 
arteriolar vasodilators have no beneficial effects on 
HRQoL. In addition, the use of β-blockers, thiazide di-
uretics, and older centrally acting drugs is associated 
with a reduction in sexual activity in men. Most stud-
ies assessing HRQoL in patients with hypertension 
concerned monotherapy. Combination therapy, which 
involves the use of several drugs, is more effective in 
achieving BP control but is rather associated with a re-
duction in HRQoL, although to an extent depending on 
the effect of individual drugs. It has also been shown 
that there are clear differences between antihyperten-
sive drugs within each particular drug class. Moreover, 
the duration of drug action has been shown to be im-
portant: long-acting drugs are rated higher by patients 
than drugs with short half-lives. Since the HRQoL of 
untreated patients with hypertension is lower than that 
of healthy individuals, once initiating the treatment, it is 
necessary to consider the choice of a drug that would 
potentially improve the particular aspects of HRQoL.
CONCLUSIONS
To summarize, the improvement in HRQoL dur-
ing antihypertensive treatment may be expected 
in relatively young patients, with rather short dis-
ease duration and higher educational status, as 
well as who are currently employed and have no 
comorbidities. In order to obtain improvement, it is 
necessary to achieve and maintain BP control with 
at least 1 or 2 long-acting antihypertensive drugs. 
However, despite a careful drug selection to meet 
individual patients’ needs and address their mental, 
physical, and social condition, the improvement in 
the QoL of most hypertensives is still a challenge 
for physicians.
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